Soenksen Steps Down as CEO of Aperio; Will Focus on Customer Partnerships and Development

Aperio Strengthens Executive Team, Intends to Develop Deeper Customer Partnerships and Speed Innovation

Aperio Founder to focus on Customers and New Solutions; recruits David Schlotterbeck as CEO to lead Commercialization

Vista, CA –November 8, 2011 – Aperio, the global leader in providing digital pathology solutions that improve patient care, has announced that Dirk G. Soenksen, Aperio founder, President of the Digital Pathology Association, and inventor of the first ultra-fast scanner for digital pathology, will focus on customer partnership and leading the development and marketplace adoption of digital pathology solutions.

In his new role as President and Futurist, Soenksen will focus on creating deeper partnerships with customers and accelerating the development of innovative solutions that will enable pathologists to expand the scope of their practice and gain access to new tools that will enhance their role in providing personalized medicine.

“Aperio’s accelerating growth has created the need for additional leadership.  We have more systems installed than all competitors combined.  In addition, we have an exciting and well defined product roadmap that will enable pathologists to be more effective in supporting the patient’s care team,” said Soenksen.  “I intend to focus my time on customer needs, partnerships and on the execution of product and solution development.” 

“I am excited to have recruited David Schlotterbeck, retired CEO of CareFusion, to serve as Chief Executive Officer of Aperio.  Splitting leadership responsibilities allows the company to execute and scale with increasing speed,” said Soenksen. “Dave has a proven 20-year track record of creating value in the healthcare space and I look forward to working with Dave as he leads our efforts to commercialize our products and solutions globally.” 

“I am delighted to serve as CEO of Aperio and to work with Dirk and the Aperio team to improve patient care through digital pathology,” said Schlotterbeck. “I am stepping back into a full-time role because of my excitement about the business opportunity for Aperio to deliver products and solutions that can positively impact the practice of pathology.  Adoption of digital pathology is accelerating globally and I’m thrilled to help Aperio achieve worldwide growth.”